FINWIRES · TerminalLIVE
FINWIRES

$ABT

25 stories mentioning ABT

Every FINWIRES story that references ABT, newest first.

Sectors

Sector Update: Health Care Stocks Mixed Premarket Thursday

Health care stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly higher and the iShares Biotechnology ETF (IBB) down 0.1%.Abbott Laboratories (ABT) stock was down more than 3% after the company issued Q2 adjusted earnings per share guidance below analysts' expectations, and lowered its 2026 adjusted EPS outlook.Hims & Hers Health (HIMS) shares were up more than 7% after a senior US health official signaled plans to ease restrictions on certain peptides.Organon (OGN) is a potential acquisition target by India's Sun Pharmaceutical Industries, Germany's Grunenthal, and private equity firms, Bloomberg reported, citing unnamed people familiar with the matter. Organon shares were up more than 5% pre-bell.

$ABT$HIMS$IBB$OGN$XLV
Research

Research Alert: Abt Q1 In Line With Expectations Amid Nutrition Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Abbott delivered Q1 2026 results aligned with expectations, reporting adjusted EPS of $1.15 (+6% Y/Y) matching consensus and total sales of $11.164B (+7.8% Y/Y reported, +3.7% comparable). The successful completion of the Exact Sciences acquisition on March 23 established Abbott as a leader in oncology diagnostics, in our view, contributing $96M in Cancer Diagnostics sales (+13.4% Y/Y comparable). Abbott updated full-year 2026 guidance projecting comparable sales growth of 6.5%-7.5% Y/Y (unchanged) and adjusted EPS of $5.38-$5.58, including $0.20 dilution from the deal. Medical Devices continued strong performance with $5.54B in sales (+13.2% Y/Y), while Diabetes Care maintained positioning at $2.080B (+7.4% Y/Y comparable). However, Nutrition faced headwinds with sales declining to $2.017B (-7.7% Y/Y comparable), particularly in U.S. pediatric business. We believe the EXAS integration positions Abbott well in the ~$60B U.S. cancer screening market, though Nutrition segment recovery remains key to monitor.

$ABT
Sectors

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.4%.The iShares Biotechnology ETF (IBB) shed 1.7%.In corporate news, AbbVie (ABBV) is expected to report Q1 earnings within its guidance range, but that may not be enough to improve sentiment toward the drugmaker, RBC Capital Markets said in a client note. The brokerage expects AbbVie to report per-share earnings of $2.59 for the first quarter, while the current consensus on FactSet is for non-GAAP EPS of $2.83. AbbVie shares were down 2.1%.Replimune (REPL) shares tumbled 19%. The company's biologics license application for vusolimogene oderparepvec to treat unresectable advanced cutaneous melanoma was rejected by the US Food and Drug Administration, the regulator said in a complete response letter.Abbott Laboratories (ABT) has been ordered by a jury in Chicago to pay $53 million in compensatory damages to a group of families related to four cases over its infant formula, the Chicago Tribune reported. The families accused the company of allegedly failing to inform them that its infant formula could develop a dangerous intestinal disease in premature infants, the report said. Abbott shares fell 2.7%.Organon (OGN) is closing in on a deal to be acquired by Sun Pharmaceutical Industries for $12 billion, The Economic Times reported. Organon shares surged 27%.

$ABBV$ABT$OGN$REPL
Sectors

Sector Update: Health Care Stocks Lower Friday Afternoon

Health care stocks declined Friday afternoon, with the NYSE Health Care Index decreasing 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1.2%.The iShares Biotechnology ETF (IBB) dropped 1.8%.In corporate news, Replimune (REPL) shares tumbled 19%. The company's biologics license application for vusolimogene oderparepvec to treat unresectable advanced cutaneous melanoma was rejected by the US Food and Drug Administration, the regulator said in a complete response letter.Abbott Laboratories (ABT) has been ordered by a jury in Chicago to pay $53 million in compensatory damages to a group of families related to four cases over its infant formula, the Chicago Tribune reported. The families accused the company of allegedly failing to inform them that its infant formula could develop a dangerous intestinal disease in premature infants, the report said. Abbott shares fell 2.9%.Organon (OGN) is closing in on a deal to be acquired by Sun Pharmaceutical Industries for $12 billion, The Economic Times reported. Organon shares surged 23%.

$ABT$OGN$REPL
Sectors

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

Health care stocks were mixed pre-bell Friday, with the iShares Biotechnology ETF (IBB) 0.5% higher and the State Street Health Care Select Sector SPDR ETF (XLV) marginally lower.Telix Pharmaceuticals (TLX) shares were up more than 5% after the company said the US Food and Drug Administration accepted its resubmitted new drug application for its investigational glioma imaging agent Pixclara.Abbott Laboratories (ABT) has been ordered by a jury in Chicago to pay $53 million in compensatory damages to a group of families related to four cases over its infant formula, the Chicago Tribune reported. Shares of Abbott Laboratories were down 0.9% premarket.Vanda Pharmaceuticals (VNDA) said it is calling on the US Food and Drug Administration to withdraw a proposal in the regulator's fiscal 2027 Congressional Budget Justification that would extend drug review timelines. Vanda Pharmaceuticals stock was up more than 1% pre-bell.

$ABT$IBB$TLX$VNDA$XLV

Showing 21-25 of 25